Detailansicht

Wissensnetz

Person

Christoph Sarrazin

Arzt

Name	Christoph Sarrazin
Ort	Deutschland
Geschlecht	männlich
Akademischer Grad bzw. Titel	Prof. Dr. med.
Beruf	Arzt (charakteristischer Beruf) Internist Gastroenterologe
Variante	C. Sarrazin Christoph Michael Sarrazin
Datensatztyp	Person
GND-Nummer	1027125077
Datensatz-ID	1027125077
Beteiligt an alle anzeigen Sub-optimal therapy of patients with primary biliary cholangitis (PBC) in the real-life stetting of the German PBC cohort SARS-CoV-2 neutralizing antibody therapies: an early retrospective cohort study of 26 hospitalized patients treated with bamlanivimab or casirivimab/imdevimab Weight gain after interferon-free treatment of chronic hepatitis C — results from the German Hepatitis C-Registry (DHC-R) Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals Evaluation of point shear wave elastography using acoustic radiation force impulse imaging for longitudinal fibrosis assessment in patients with HBeAg-Negative HBV infection Weight Gain after Interferon-Free Treatment of Chronic Hepatitis C—Results from the German Hepatitis C-Registry (DHC-R) Epistatic interactions promote persistence of NS3-Q80K in HCV infection by compensating for protein folding instability Non-invasive assessment of fibrosis regression and portal hypertension in patients with advanced chronic hepatitis C virus (HCV)-associated liver disease and sustained virologic response (SVR): 3 years follow-up of a prospective longitudinal study Not uncommon: HBV genotype G co-infections among healthy European HBV carriers with genotype A and E infection Point shear‐wave elastography using acoustic radiation force impulse imaging for the prediction of liver‐related events in patients with chronic viral hepatitis Evolution of HCV patient characteristics and DAA regimens in the German Hepatitis C Registry (DHC-R) in 2014 and 2015 Deutsches Hepatitis C-Register (DHC-R) – eine Zwischenbilanz 4 Jahre nach Zulassung direkt antiviraler Substanzen (DAAs) Evaluation of point shear wave elastography using acoustic radiation force impulse imaging for longitudinal fibrosis assessment in patients with HBeAg-negative HBV infection Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy S3-Leitlinie „Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus (HCV) -Infektion“ : AWMF-Register-Nr.: 021/012 S3-Leitlinie „Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus (HCV) -Infektion“ : AWMF-Register-Nr.: 021/012 Labordiagnostik in der Gastroenterologie und Hepatologie Efficacy of a 12-week simeprevir plus peginterferon/ribavirin (PR) regimen in treatment-naïve patients with Hepatitis C virus (HCV) genotype 4 (GT4) infection and mild-to-moderate fibrosis displaying early on-treatment virologic response Hepatitis C : aktuelle Empfehlung zur Therapie der chronischen Hepatitis C HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infection HCVerso3 : an open-label, phase IIb study of Faldaprevir and Deleobuvir with Ribavirin in hepatitis C virus genotype-1b-infected patients with cirrhosis and moderate hepatic impairment Investigation of NS3 protease resistance-associated variants and phenotypes for the prediction of treatment response to HCV triple therapy Resistance analyses of HCV NS3/4A protease and NS5B polymerase from clinical studies of deleobuvir and faldaprevir Viral kinetics for individualized treatment durations Consideration of viral resistance for optimization of direct antiviral therapy of hepatitis C virus genotype 1-infected patients Ombitasvir, Paritaprevir, Ritonavir + Dasabuvir : Therapieregime zur Behandlung der chronischen Hepatitis C, das 3 direkt antiviral wirksame Substanzen mit unterschiedlichen Wirkmechanismen kombiniert Oxidized low-density lipoprotein is a novel predictor of interferon responsiveness in chronic Hepatitis C infection Performance and value of IFN-lambda3 and IFN-lambda4 genotyping in patients with chronic hepatitis C (CHC) genotype 2/3 in a real world setting Primary Biliary Acids Inhibit Hepatitis D Virus (HDV) Entry into Human Hepatoma Cells Expressing the Sodium-Taurocholate Cotransporting Polypeptide (NTCP) Reply to: "Evidence supporting a beneficial role of vitamin D in chronic hepatitis C" Vitamin D Levels Vary during Antiviral Treatment but Are Unable to Predict Treatment Outcome in HCV Genotype 1 Infected Patients PEG-IFN alpha but not ribavirin alters NK cell phenotype and function in patients with chronic hepatitis C Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C Vitamin D levels vary during antiviral treatment but are unable to predict treatment outcome in HCV genotype 1 infected patients A multicenter study on the role of direct retrograde cholangioscopy in patients with inconclusive endoscopic retrograde cholangiography Association of IFNL3 rs12979860 and rs8099917 with biochemical predictors of interferon responsiveness in chronic hepatitis C virus infection Baseline MELD score predicts hepatic decompensation during antiviral therapy in patients with chronic hepatitis C and advanced cirrhosis SEMS vs cSEMS in duodenal and small bowel obstruction : high risk of migration in the covered stent group A frequent variant in the human bile salt export pump gene ABCB11 is associated with hepatitis C virus infection, but not liver stiffness in a German population Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers A common HLA-DPA1 variant is associated with hepatitis B virus infection but fails to distinguish active from inactive Caucasian carriers A frequent variant in the human bile salt export pump gene ABCB11 is associated with hepatitis C virus infection, but not liver stiffness in a German population A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis C Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers High prevalence of anti-HCV antibodies in two metropolitan emergency departments in Germany : a prospective screening analysis of 28,809 patients Soluble serum CD81 is elevated in patients with chronic hepatitis C and correlates with alanine aminotransferase serum activity Aktualisierung der S 3-Leitlinie zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion : AWMF-Register-Nr.: 021 / 011 A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants Dual function of the NK cell receptor 2B4 (CD244) in the regulation of HCV-specific CD8+ T cells Portal vein thrombosis as complication of romiplostim treatment in a cirrhotic patient with hepatitis C-associated immune thrombocytopenic purpura Reply to "Vitamin D deficiency and HCV chronic infection: What comes first?" Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis Update der S 3-Leitlinie Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus(HCV)-Infektion, AWMF-Register-Nr.: 021 / 012 Hepatitis C im Dialog : 100 Fragen - 100 Antworten ; 11 Tabellen Letalität auf der Warteliste und Transplantation bei Leberallokation nach MELD Score in Deutschland - erste prospektive Ergebnisse bei 100 Patienten Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus Treatment predictors of a sustained virologic response in hepatitis B and C

Hinweis

Die Betaversion beinhaltet noch nicht alle Funktionen und Informationen des Katalogs des DNB-Portals. Falls Sie Informationen vermissen oder ein Medium bestellen wollen, besuchen Sie bitte die entsprechende Seite im Katalog des DNB-Portals über folgenden Link:

Katalog der Deutschen Nationalbibliothek

Christoph Sarrazin

Sub-optimal therapy of patients with primary biliary cholangitis (PBC) in the real-life stetting of the German PBC cohort

SARS-CoV-2 neutralizing antibody therapies: an early retrospective cohort study of 26 hospitalized patients treated with bamlanivimab or casirivimab/imdevimab

Weight gain after interferon-free treatment of chronic hepatitis C — results from the German Hepatitis C-Registry (DHC-R)

Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals

Evaluation of point shear wave elastography using acoustic radiation force impulse imaging for longitudinal fibrosis assessment in patients with HBeAg-Negative HBV infection

Weight Gain after Interferon-Free Treatment of Chronic Hepatitis C—Results from the German Hepatitis C-Registry (DHC-R)

Epistatic interactions promote persistence of NS3-Q80K in HCV infection by compensating for protein folding instability

Non-invasive assessment of fibrosis regression and portal hypertension in patients with advanced chronic hepatitis C virus (HCV)-associated liver disease and sustained virologic response (SVR): 3 years follow-up of a prospective longitudinal study

Not uncommon: HBV genotype G co-infections among healthy European HBV carriers with genotype A and E infection

Point shear‐wave elastography using acoustic radiation force impulse imaging for the prediction of liver‐related events in patients with chronic viral hepatitis

Evolution of HCV patient characteristics and DAA regimens in the German Hepatitis C Registry (DHC-R) in 2014 and 2015

Deutsches Hepatitis C-Register (DHC-R) – eine Zwischenbilanz 4 Jahre nach Zulassung direkt antiviraler Substanzen (DAAs)

Evaluation of point shear wave elastography using acoustic radiation force impulse imaging for longitudinal fibrosis assessment in patients with HBeAg-negative HBV infection

Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy

S3-Leitlinie „Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus (HCV) -Infektion“ : AWMF-Register-Nr.: 021/012

S3-Leitlinie „Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus (HCV) -Infektion“ : AWMF-Register-Nr.: 021/012

Labordiagnostik in der Gastroenterologie und Hepatologie

Efficacy of a 12-week simeprevir plus peginterferon/ribavirin (PR) regimen in treatment-naïve patients with Hepatitis C virus (HCV) genotype 4 (GT4) infection and mild-to-moderate fibrosis displaying early on-treatment virologic response

Hepatitis C : aktuelle Empfehlung zur Therapie der chronischen Hepatitis C

HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infection

HCVerso3 : an open-label, phase IIb study of Faldaprevir and Deleobuvir with Ribavirin in hepatitis C virus genotype-1b-infected patients with cirrhosis and moderate hepatic impairment

Investigation of NS3 protease resistance-associated variants and phenotypes for the prediction of treatment response to HCV triple therapy

Resistance analyses of HCV NS3/4A protease and NS5B polymerase from clinical studies of deleobuvir and faldaprevir

Viral kinetics for individualized treatment durations

Consideration of viral resistance for optimization of direct antiviral therapy of hepatitis C virus genotype 1-infected patients

Ombitasvir, Paritaprevir, Ritonavir + Dasabuvir : Therapieregime zur Behandlung der chronischen Hepatitis C, das 3 direkt antiviral wirksame Substanzen mit unterschiedlichen Wirkmechanismen kombiniert

Oxidized low-density lipoprotein is a novel predictor of interferon responsiveness in chronic Hepatitis C infection

Performance and value of IFN-lambda3 and IFN-lambda4 genotyping in patients with chronic hepatitis C (CHC) genotype 2/3 in a real world setting

Primary Biliary Acids Inhibit Hepatitis D Virus (HDV) Entry into Human Hepatoma Cells Expressing the Sodium-Taurocholate Cotransporting Polypeptide (NTCP)

Reply to: "Evidence supporting a beneficial role of vitamin D in chronic hepatitis C"

Vitamin D Levels Vary during Antiviral Treatment but Are Unable to Predict Treatment Outcome in HCV Genotype 1 Infected Patients

PEG-IFN alpha but not ribavirin alters NK cell phenotype and function in patients with chronic hepatitis C

Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis

Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C

Vitamin D levels vary during antiviral treatment but are unable to predict treatment outcome in HCV genotype 1 infected patients

A multicenter study on the role of direct retrograde cholangioscopy in patients with inconclusive endoscopic retrograde cholangiography

Association of IFNL3 rs12979860 and rs8099917 with biochemical predictors of interferon responsiveness in chronic hepatitis C virus infection

Baseline MELD score predicts hepatic decompensation during antiviral therapy in patients with chronic hepatitis C and advanced cirrhosis

SEMS vs cSEMS in duodenal and small bowel obstruction : high risk of migration in the covered stent group

A frequent variant in the human bile salt export pump gene ABCB11 is associated with hepatitis C virus infection, but not liver stiffness in a German population

Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers

A common HLA-DPA1 variant is associated with hepatitis B virus infection but fails to distinguish active from inactive Caucasian carriers

A frequent variant in the human bile salt export pump gene ABCB11 is associated with hepatitis C virus infection, but not liver stiffness in a German population

A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis C

Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers

High prevalence of anti-HCV antibodies in two metropolitan emergency departments in Germany : a prospective screening analysis of 28,809 patients

Soluble serum CD81 is elevated in patients with chronic hepatitis C and correlates with alanine aminotransferase serum activity

Aktualisierung der S 3-Leitlinie zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion : AWMF-Register-Nr.: 021 / 011

A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants

Dual function of the NK cell receptor 2B4 (CD244) in the regulation of HCV-specific CD8+ T cells

Portal vein thrombosis as complication of romiplostim treatment in a cirrhotic patient with hepatitis C-associated immune thrombocytopenic purpura

Reply to "Vitamin D deficiency and HCV chronic infection: What comes first?"

Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma

Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis

Update der S 3-Leitlinie Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus(HCV)-Infektion, AWMF-Register-Nr.: 021 / 012

Hepatitis C im Dialog : 100 Fragen - 100 Antworten ; 11 Tabellen

Letalität auf der Warteliste und Transplantation bei Leberallokation nach MELD Score in Deutschland - erste prospektive Ergebnisse bei 100 Patienten

Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus

Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus

Treatment predictors of a sustained virologic response in hepatitis B and C